AbbVie (ABBV) Cash from Financing Activities (2012 - 2026)
AbbVie (ABBV) posted quarterly Cash from Financing Activities of $919.0 million for Q1 2026, up 173.05% year-over-year from $336.6 million in Q1 2025, and up 122.06% quarter-over-quarter from -$4.2 billion in Q4 2025.
AbbVie (ABBV) Cash from Financing Activities (2012 - 2026) Analysis & Trends
AbbVie (ABBV) has reported Cash from Financing Activities for 15 consecutive years, with $919.0 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Cash from Financing Activities rose 173.05% year-over-year to $919.0 million; the TTM figure through Mar 2026 stood at -$10.5 billion (up 38.99% YoY), while the FY2025 annual figure was -$12.7 billion, down 144.18% from the prior year.
- Cash from Financing Activities advanced to $919.0 million in Q1 2026 per ABBV's latest filing, from -$4.2 billion in the prior quarter.
- Across five years, Cash from Financing Activities topped out at $10.8 billion in Q1 2024 and bottomed at -$9.6 billion in Q4 2022.
- Historically, Cash from Financing Activities has averaged -$3.5 billion across 5 years, with a median of -$4.2 billion in 2025.
- Annual changes were most pronounced in 2022 — Cash from Financing Activities sank 119.66% — and 2024, when it jumped 274.73%.
- AbbVie's Cash from Financing Activities stood at -$9.6 billion in 2022, then jumped by 53.82% to -$4.4 billion in 2023, then plunged by 54.21% to -$6.9 billion in 2024, then jumped by 39.28% to -$4.2 billion in 2025, then surged by 122.06% to $919.0 million in 2026.
- Business Quant data shows ABBV's Cash from Financing Activities at $919.0 million in Q1 2026, -$4.2 billion in Q4 2025, and -$4.6 billion in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | -8.78 Bn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | -5.05 Bn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | 1.76 Bn |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | -2.02 Bn |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | -3.89 Bn |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | -1.48 Bn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | 2.34 Bn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | -3.66 Bn |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | - |
| 10 | Sanofi | 55.07 Bn | 47.69 Bn | 10.79 Bn | -2.10 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -5.05 Bn |
| Jun 30, 2026 | -5.05 Bn |
| Mar 31, 2026 | 919.00 Mn |
| Mar 31, 2026 | 919.00 Mn |
| Dec 31, 2025 | -4.17 Bn |
| Dec 31, 2025 | -4.17 Bn |
| Sep 30, 2025 | -4.59 Bn |
| Sep 30, 2025 | -4.59 Bn |
| Jun 30, 2025 | -2.71 Bn |
| Jun 30, 2025 | -2.71 Bn |
| Mar 31, 2025 | -1.26 Bn |
| Mar 31, 2025 | -1.26 Bn |
| Dec 31, 2024 | -6.86 Bn |
| Dec 31, 2024 | -6.86 Bn |
| Sep 30, 2024 | -3.07 Bn |
| Sep 30, 2024 | -3.07 Bn |
| Jun 30, 2024 | -6.10 Bn |
| Jun 30, 2024 | -6.10 Bn |
| Mar 31, 2024 | 10.82 Bn |
| Mar 31, 2024 | 10.82 Bn |